PET
An Open Label Positron Emission Tomography (PET) Study Using 2-[18F]-F-A85380 to Determine α4β2 Neuronal Nicotinic Receptor Occupancy of AZD3480 After Oral Administration to Healthy Male Subjects (Non Nicotine Users)
Sponsor study identifier
Secondary identifiers
interventional
9
1 country
1
Study Start
January 2008
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
August 2008
Actual (reported)Study Completion
August 2008
Actual (reported)The study is being performed in order to learn more about AZD3480 (potential as treatment for patients with Alzheimer's Disease) and to investigate how much of AZD3480 is bound to the nicotinic receptors in the brain at different concentrations of AZD3480 in blood, as well as to investigate the period of time for this binding.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 2008
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 2008
Date type not reportedThis date has not been verified as actual or estimated.
May 27, 2008
Actual (reported)May 29, 2008
Actual (reported)August 2008
Actual (reported)August 2008
Actual (reported)Plasma concentration (AUC, Cmax, tmax)
During time period of the PET assessement
The whole brain uptake and regional distribution of radioligand 2-[18F]-F-A85380 following single intravenous (iv) microdose will be assessed (using derived radioactivity measurements).
One on baseline day and one at the drug treatment day
SafetyAEs and vital signs.
During the whole study
single dose, oral
Single dose, IV
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Research Site
Stockholm, Sweden
Hans-Göran, Hårdemark, MD, PhD
Clinical Neuroscience TA AstraZeneca R&D Södertälje, Sweden
Bo Fransson, MD
AstraZeneca Clinical Pharmacology Unit, C2-84, Karolinska University Hospital Huddinge, Stockholm, Sweden
9 participants (actual enrollment reported by the registry).
First Submitted
May 27, 2008
First Posted
May 29, 2008
Study Start
January 2008
Date type not reportedThis date has not been verified as actual or estimated.
An Open Label Positron Emission Tomography (PET) Study to Determine Central mGluR5 Receptor Occupancy of AZD2516
Contact the study team to confirm eligibility.
Primary Completion
August 2008
Actual (reported)Study Completion
August 2008
Actual (reported)Last Updated
December 10, 2010
Record last verified: 2008-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: